Antibodies Events Announce Your Event Here

18–22 March 2019 Immuno-Oncology Summit Europe 2019

London, UK

Following year-on-year success, CHI is excited about presenting a much enlarged SIX-TRACK Immuno-Oncology Summit Europe for March 18-22 2019 in the heart of London's Canary Wharf. During a full week of cutting-edge science and discussion, delegates will hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics. Register early for maximum savings. For more information or to register, visit

10–11 December 2018 Immunotherapies for Infectious Diseases Congress 2018

Lyon, France

We are pleased to invite you to attend the 2nd International Immunotherapies for Infectious Diseases Congress (I4ID2018) that will be held on December 10-11, 2018 in Lyon, France. The I4ID Congress, organized by MabDesign and BIOASTER, will bring together pharmaceutical industries, research labs, clinicians, service providers, technology developers and policy makers to exchange about the development of immunotherapy solutions for prevention and treatment of infectious diseases. This year edition is dedicated to “Host directed Therapies (HDT) to fight Infectious Diseases”.

Keynote Speakers are:

Stefan H.Kaufmann–Institute for Infection Biology, Germany/Charité University Clinics, Germany

Richard Hotchkiss–Washington University School of Medicine, USA

Pierre François Laterre–St Luc University Hospital, Belgium

Moreover, we have currently an open Call for abstracts to give a Pitch and/or present a Poster until September 28th.

Share your innovative products, new technologies and research projects at the Pitch Session “Innovation on HDT approaches to treat Infectious diseases” or during the Poster session!

Check the guidelines to submit your abstract. You can find more information about the program at

12–16 November 2018 10th Annual PEGS Europe

Lisbon, Portugal

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. In 2017, for the sixth year in a row, a record number of delegates participated in PEGS Europe, as more than 900 attendees from 35 countries convened in beautiful Lisbon, Portugal to discuss the latest advances in protein and antibody engineering. The 2018 event will feature:
- 1,000 attendees
- 225 technical presentations
- 150+ scientific posters
- Dedicated networking opportunities
- Exclusive exhibit & poster viewing hours
- Interactive roundtable, breakout & panel discussions

12–15 November 2018 World ADC San Diego

San Diego, CA, USA

World ADC San Diego is the industry’s longest standing and most comprehensive antibody-drug conjugate conference.

Across multiple-streams of learning, World ADC will cover every element of ADC drug development from construct design to improving preclinical predictability and product manufacturability. This leading antibody-drug conjugate event will provide you with an unparalleled breadth and depth of content.

Don’t miss this opportunity to join your fellow scientists at the heart of the ADC community. Join 650+ of your peers, from 220 organizations for your most valuable ADC learning and networking opportunity of 2018.

29–31 October 2018 World Biosimilar Congress 2018

Congress Centre, Basel, Switzerland

Cost-effective biologics for payers, prescribers and patients

2017 was our biggest event to date and it was a real inflection point for the industry. After several approvals in the US, the Biosimilar Industry is now finally ready to fulfil its promise and become a multi-billion-dollar business providing real benefits to healthcare. On the back of these approvals it is becoming a far more crowded and competitive landscape but getting a biosimilar to the patient still presents a number of challenges that the World Biosimilar Congress will look to address.
Across the two days, industry and thought-leading speakers from across the globe will come together to network and discuss the key issues on biosimilar drug development, commercialisation, market access and healthcare uptake.
As part of the Festival of Biologics, the World Biosimilar Congress will be co-located with European Antibody Congress, World Immunotherapy Congress and HPAPI World Congress.
Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
Register today and benefit from the 15% partner discount. Simply use the voucher code VTTY when you register online here Why not bring your colleagues along too? Book a group of 3+ people and get an additional 20% off!

29–31 October 2018 Clinical Trials Congress 2018

Congress Centre, Basel, Switzerland

Achieving Clinical Success: A multi-streamed, co-located conference & technology exhibition

Over recent years, there has been increased discussion about the challenges facing pharma and biotech clinical trials. With only 32% of drugs making it through to Phase III trials, and 10% making it to market, it is vital that the industry focuses on new ways to increase this success rate.  
That is why we have created an event that breaks down the silos of clinical trial development. Bringing together 30+ speakers from pharma, biotech, CROs and technology innovators, the clinical trials event will aim to help tackle the challenges around clinical trials, such as: Data and Analytics, Patient Recruitment, Planning and Trial Design, Site Selection and Management and much more.
Part of the Festival of Biologics that brings together 4 co-located conferences (the European Antibody Congress, the World Immunotherapy Congress, the World Biosimilar Congress and the HPAPI World Congress), you’ll have the opportunity to network with 300+ speakers, 80 sponsors and exhibitors and 1,000 attendees.
Join us at the Basel Congress Centre this October 29th–30th and help shape the future of clinical research, outsourcing and partnering strategies.
Register today and benefit from the 15% partner discount. Simply use the voucher code TXZQ when you register here Why not bring your colleagues along too? Book a group of 3+ people and get an additional 20% off!

29–31 October 2018 European Antibody Congress 2018

Congress Centre, Basel, Switzerland

Discover. Develop. Get to market. A multi-streamed, co-located conference & technology exhibition.

In the 13 years that the European Antibody Congress has run, there have been countless breakthroughs, advancements and achievements that not only were showcased for the first time at the European Antibody Congress, but were also born out of collaborations and partnerships that were catalysed by, or initiated, at the European Antibody Congress.
Our mission, for every European Antibody Congress, is to bring you the very best speakers from big pharma, biotechs, academia and technology innovators to discuss with you the most exciting breakthroughs when it comes to the discovery and development of antibodies. Whether that’s the newest format of a cancer killing ADC, the most advanced screening technology for mAbs, or the clinical development of a bispecific with promises to treat Alzheimer’s disease, we want to give you access to all of this to grow your knowledge, grow your business, and grow your connections.
Over the years, the European Antibody Congress programme has grown from strength to strength. This year, we are adding more streams allowing us to focus more heavily on protein engineering, antibody R&D, CMC and developability and bioprocessing. Brand new topics include AI for antibody discovery, co-formulation of biologics, safety and toxicity, and orally bioavailable biologics.
As part of the Festival of Biologics, the European Antibody Congress will be co-located with World Biosimilar Congress, World Immunotherapy Congress and HPAPI World Congress. Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
Register today and benefit from the 15% partner discount. Simply use the voucher code KTTF when you register online here Why not bring your colleagues along too? Book a group of 3+ people and get an additional 20% off!

29–31 October 2018 World HPAPI Congress 2018

Congress Centre, Basel, Switzerland

Europe’s marketplace for high potency API development and manufacturing

The HPAPI World Congress has been developed over 4 years as the only two tracked HPAPI Congress. The event has a strong focus on the management of HPAPI, Design of Facilities, Innovation of New HPAPI’s, SHE, Working with CMOs and case studies. We have a diverse group of companies and consultants along with a mix of different formats to provide the best possible learning experience for our participants. We will be presenting many first releases on the event including understanding a new class of ADC linker and discussing new factories in development. There are a range of new questions about the management of HPAPIs including the banding of agents.
As part of the Festival of Biologics, the HPAPI World Congress will be co-located with World Biosimilar Congress, World Immunotherapy Congress and European Antibody Congress. Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
Register today and benefit from the 15% partner discount. Simply use the voucher code PWPV when you register online here Why not bring your colleagues along too? Book a group of 3+ people and get an additional 20% off!

29–31 October 2018 World Immunotherapy Congress 2018

Basel Congress Center, Switzerland, Basel

Discover. Develop. Bring to market. For biotech, pharma and their partners.

Our vision is to bring together the full community and provide a single meeting point for the whole value chain. It is where science meets business to make immunotherapy the cornerstone of the fight against cancer.
For the third instalment of the World Immunotherapy Congress, we have introduced more content allowing us to delve deeper into the case studies, clinical trials and immunotherapy discovery than ever before.
With two full tracks of content over the three days, covering oncology, non-oncology (infectious disease, inflammation, autoimmune disorders, organ transplant and neurological disease), oncolytics, cancer vaccines, safety, and efficacy, we are covering all bases.
As part of the Festival of Biologics, the World Immunotherapy Congress will be co-located with World Biosimilar Congress, European Antibody Congress and HPAPI World Congress. Attendees will have access to plenty of content across the 3 days and more networking opportunities than ever before with over 800+ leading industry professionals.
Register today and benefit from the 15% partner discount. Simply use the voucher code FLDH when you register online here Why not bring your colleagues along too? Book a group of 3+ people and get an additional 20% off!

29 June–1 July 2018 Antibodies and complement: Effector functions, therapies and technologies

Girona, Spain

This 4-day conference will focus attention on key advances in the fields of antibodies, complement and their receptors. 21 invited speakers, 19 oral presentations selected from submitted abstracts, and 2 poster sessions will enable productive exchanges and publicity around your projects and achievements. Attendance is capped at 150. The conference will present recent advances in these exciting fields, in an informal setting designed to maximize interaction. The 4* venue possesses outside pools overseeing the Mediterranean Sea, with direct access to the beach (daily free time slots). >20 travel grants available for students/post-docs.

Topics and Speakers:

2 Keynote Sessions: Paul Parren (U. of Leiden, NL) & George Georgiou (UT Austin, USA)
Novel IgG & complement functions
Structure function relations
Regulation of function & glycosylation
Technological advances
Ab and complement receptors
2 poster sessions with prizes

27–28 June 2018 World ADC Asia

Shanghai, China

Focused on ADC drug development, World ADC Asia will enable you to propel your antibody-drug conjugate pipeline into clinical development. Join 80+ ADC experts from the world’s leading ADC companies to network with potential collaborators and cement existing partnerships.

Designed with AbGenomics, Roche and RemeGen and other leading ADC organisations this forum will enable you to explore novel linker technologies for enhanced in vivo stability, confidently meet regulatory quality specifications for biosimilar candidates and confidently outsource to your chosen CMO.

This is the only ADC focused conference that will bring together all the key players both from within Asia, the US and Europe.

25–26 June 2018 6th Antibody Industrial Symposium 2018 (AIS2018)

CORUM Congress Center

The 6th Antibody Industrial Symposium 2018 (AIS2018) congress, organized by the LabEx MAbImprove and MabDesign, offers an ideal conference for scientists, industries, physicians and policy makers to exchange about therapeutic antibodies.

The scientific Committee has set-up an exciting program focusing on the following theme: “Targets for mAbs: Innovative Approaches for their Discovery & Validation”.

The 2 days program includes keynote lectures, pitch talks of new creative projects, industrial talks from pharmaceutical companies and a poster session. Furthermore, there will be several opportunities for networking, companies to showcase their new products and technologies as well as dedicated time for business partnering.

The topics covered during this meeting are:

-Validated Targets: lessons learned from success & failure in clinical

-Discovery Approaches: Accessing clinical material, Target Identification platforms, OMICS-based analysis

-New Approaches/Technologies for Discovery & Validation of New Targets for mAbs

-Pre-Clinical Validation: Methods, Models & Companion tests

-Emerging Targets: Immunocheckpoints & Microenvironment

Visit the AIS2018 website to know more and register !:

24–25 May 2018 PEGS: Medical Biotechnology

Ghent, Belgium

With this conference on Medical Biotechnology, VIB will bring together experts in the field to discuss the new developments and future challenges in this field. Four plenary sessions will cover biopharmaceutical technology, targeted delivery, diagnostics & biomarkers and vaccines.

In addition to the scientific sessions there will be ample opportunities to network during the breaks, posters sessions, reception and conference dinner.

24–25 May 2018 3rd Annual Advances in Immuno-Oncology Congress

London, UK

Oxford Global is proud to present the 3rd Annual Advances in Immuno-Oncology Congress taking place on 24–25 May 2018 in London, UK, featuring over 50 presentations in a revamped conference programme that ensures you will benefit from the latest case studies and high-level scientific debate.

Discussion ranges across a variety of therapeutic strategies, from the discovery of combination therapies to vaccines to checkpoint inhibitors. Further talks look at genomic approaches to cancer immunotherapy and the impact of growing microbiome research on immuno-oncology.

6 interactive streams:

  • Discovery of Immuno-Oncology Therapies
  • Translational Immuno-Oncology
  • Genomics in Cancer Immunotherapy and Precision Medicine
  • Preclinical Development: Screening, Assays and Modelling in Immuno-Oncology
  • Immuno-Oncology Therapeutics Approaches: Clinical Research and Clinical Trials
  • Microbiome in Immuno-Oncology

View the Agenda here:

Key Speakers include Chief Executives and Directors from AstraZeneca, Merck, GlaxoSmithKline, Glycostem and many more. The two-day congress offers an interactive platform for high level scientific and business discussions, ensuring valuable networking and interactive sessions.

14 pre-scheduled one to one meetings, exhibition and informal networking opportunities

17–18 May 2018 3rd Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

Barcelona, Spain

Key Practical Learning Points of the Summit:

  • 360 ° view of Antibody Drug Conjugates (ADC) from key industry players to leverage for the business and scientific adoption
  • Emerging discoveries, cutting-edge knowledge, tools, methods, technologies to design and to bring to the clinic safe and efficient ADCs
  • Advances accelerating ADC therapies success

We are pleased to invite you to the 3rd Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 17-18, 2018 in Barcelona, Spain.

This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development.

The summit will shed light on:


  • Better understandable, more precise and new targets
  • Alternative scaffolds and new payloads
  • Optimized conjugation chemistry and stability
  • Improved therapeutic index                                                                                                             


  • ADC to treat tumours of the hematopoietic and lymphoid tissues
  • ADC to treat solid tumours
  • ADC to treat non-oncology diseases
  • ADC - immuno-oncology combinations
  • Bispecific - ADC combinations


It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Barcelona in May!

30 April–4 May 2018 PEGS: The Essential Protein Engineering Summit

Boston, MA, USA

The Essential Protein Engineering Summit is one of the industry’s preeminent events that inspires accelerated biotherapeutic protein drug development. This weeklong event attracts over 2,300 international participants, and features nearly 400 presentations by world renowned leaders from pharma, academia, and government showcasing case studies, cutting edge data, insight and perspective. Conference programs include a broad spectrum of topics including protein and antibody engineering, cancer immunotherapy, oncology, and emerging therapeutics. Learn more at

16–17 April 2018 5th Annual Biosimilars & Biobetters Congress

London, UK

Oxford Global Conferences are proud to present the 5th Annual Biosimilars & Biobetters Congress co-located with the 11th Annual Proteins & Antibodies Congress and the 5th Annual Peptides Congress, taking place on the 16-17 April 2018 in London.
Over 450 proteins, peptides and biosimilars delegates representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions
Over 20 presentations and case studies focusing on the key areas of the biosimilars industry including market access strategies, clinical development, commercialisation, manufacturing and bio-analytics
Two-day interactive conference addressing the following topics:
• Market Access Strategies, Opportunities, Clinical Development and Commercial Challenges
• Developing Biosimilars and Biobetters – Manufacturing and Bio-analytics

16–17 April 2018 11th Annual Proteins & Antibodies Congress

London, UK

Oxford Global are pleased to announce the return of the Proteins & Antibodies Congress.

Taking place in London on 16-17 April 2018, this congress will be attended by 450+ senior level experts to network about the latest developments & participate in presentations from the below main themes:

  • Protein Engineering, Design & Selection
    • Antibody Engineering, Development & Design
    • Cloning, Expression, Purification & Analytics
    • Biotherapeutics: case studies, manufacturing challenges, chemistry, analytics & control

Programme Highlights Include:

  • PD-1 Antibody: A Broad Spectrum Anti-Cancer Agent Both As Monotherapy And In Combination – Roy Baynes, Chief Medical Officer, Merck & Co., Inc.
    • Developability Assessment Of Therapeutic Proteins – Thorsten Lorenz, Group Head, Novartis
    • Integrated High Throughput Protein Purification & Analytics – Kenneth Walker, Director, Amgen
    • Developing Bispecific Antibodies For Immuno-Oncology – Syd Johnson, Vice President, Macrogenics

Society members save 20% on the registration fee! Contact us at [email protected] for the code.

26–28 March 2018 8th World ADC San Diego

Berlin (Germany)

The approval of Besponsa and re-approval of Mylotarg has fuelled the belief that ADCs are at the forefront of research in the war to fight cancer. With a further 72 ADCs in clinical development this means ADCs are putting cancer treatment on the cusp of a major breakthrough. 

These huge strides forward and more will be covered at World ADC Berlin

Now in it’s 8th year, World ADC Berlin is Europe’s longest standing and most comprehensive antibody-drug conjugate conference. Attend this meeting to develop more clinically efficacious and safe ADCs

Use promotional code ANT10 to receive a 10% discount off the current price – register online at

25–30 March 2018 2018 Antibody Biology and Engineering Gordon Research Conferences

Lucca (Barga), Italy

The unique format of the 5-day conferences is designed to maximize productive interaction and discussion between scientists. Attendance is capped at 200 and the Antibody Biology and Engineering conference is always oversubscribed.The conference will present in-depth coverage of recent advances in this exciting field, in an informal setting designed to maximize interaction.

Topics and Speakers:
Keynote Session: Therapeutic Antibodies 
Antibody Properties and Diversity 
Structure Function Relations 
Immunoglobulin Effector Function 
Antibody Cross-Talk 
Orchestrating Antibody Responses 
Alternative Antibody Dependent Responses 
Pre-Clinical Antibody Evaluation 
Keynote Session: Antibodies Therapeutics as Agents of Clinical Change 
Power Hour

19–21 March 2018 4th annual ICI Boston Summit

Boston MA

ICI Boston 2018 is focused exclusively on overcoming the preclinical, translational and clinical challenges encountered in the development of checkpoint modulators. Ensure you make the right decisions with your IO pipeline by learning from the drug developers who have successfully developed pioneering IO therapeutics.
Visit the website to learn more about the data and insights the 30+ expert speakers will share:

19–23 March 2018 Immuno-Oncology Summit Europe

Hilton Canary Wharf, London, UK

Hear from more than 50 leading immune-oncology researchers at Cambridge Healthtech Institute's Third Annual Immuno-Oncology Summit Europe, taking place 19-23 March 2018 in the heart of London’s Canary Wharf. The 2018 agenda features focused coverage of adoptive t-cell therapy, combination immunotherapy, and immunomodulatory antibodies. Keynote presenters include Bent Jakobsen (CSO, Immunocore), K. Dane Wittrup (Carbon P. Dubbs Professor, MIT), and Roy Baynes (Head of Global Clinical Development, Merck).

To learn more and to secure your place, visit Please use this tracking link:

15–16 March 2018 10th Edition of International Conference on Structural Biology 2018

Barcelona, Spain

The EuroSciCon on Structural Biology is going to be held during March15-16, 2018 at Barcelona, Spain.
The Structural biology conference focuses on the topics Analytical Techniques, Computational Chemistry,
Computational Methods and Biology, Molecular Modelling, Simulation & Molecular Graphics, Molecular Engineering,Molecular Design Software, 3D Protein Structure Predictions, Structural Bio-informatics, Drug Designing, Biomarkers & Proteomics, Databases, Chemical Biology, Biophysics, Genome Informatics and Cancer Immunotherapy.

Theme: Clustered Science Technologies for emerging & advancements in Structural Biology

By bringing together interdisciplinary researchers working in a variety of applicational areas,
this Euro Structural Biology would lay a platform for all the Academicians, Scientists, Young Researchers,
Industrial Members to interact and intend their advanced scientific researches with global eminent scientists
and accelerate progress in this area.This conference would be a great opportunity for the global scientists with
great mark of vision in the field of scientific advancing technologies.

20–22 February 2018 CAR-TCR Summit Europe

London, UK

The CAR-TCR Summit Europe (London, 20-22 February) is the leading end-to-end summit focused on the global delivery of safe, effective and commercially successful CAR and TCR cell immunotherapies. It brings you access to the leaders in this field and the hub of companies creating novel innovations in Europe. It is your opportunity to network, interact and learn as the stage is set for visionary leaders to transform the commercial and clinical delivery of cancer therapeutics with CAR-T and TCR therapies. You can gain exclusive insight on current clinical programs and case studies on the wave of next generation CAR-TCR candidates from those pioneering in this field.

Here is a quick summary of what’s new for this year’s meeting:

Solid tumours: Hear about the novel innovations being implemented to drive the killing potential of CAR-TCR therapies in solid tumour indications with Leucid Bio and T-Knife.

Safety: Ensure adverse events and toxic side effects are overcome to guarantee the safety profiles of these life-changing therapies, and ensure accessibility to broader patient populations with Pfizer and Celgene.

Manufacturing: Miltenyi Biotec highlight the most important aspects of manufacturing scale up alongside automation innovation to reduce COGs.

Regulations: With Yescarta and Kymriah still pending EMA approval, the first to market in Europe will be another huge milestone for this industry. Learn how to navigate the regulatory minefield to ensure successful market approval of your therapeutic with the Chair of the CAT.

Commercialisation: Hear from Kite Pharma and their initial commercial experience in the field.

Lessons learned: Clinical development lessons from Novartis and Adaptimmune with their advanced programmes.

13–17 November 2017 2017 PEGS Europe

Lisbon, Portugal

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. In 2016, for the fifth year in a row, a record number of delegates participated in PEGS Europe, as more than 800 attendees from 36 countries convened in beautiful Lisbon, Portugal to discuss the latest advances in protein and antibody engineering. The 2017 event will feature:
- 800+ attendees
- 200 technical presentations
- 140+ scientific posters
- Dedicated networking opportunities
- Exclusive exhibit & poster viewing hours
- Interactive roundtable, breakout & panel discussions

12–6 December 2016 Protein Discovery Summit 2016

Boston, MA, USA

This summit will discuss various areas in the field of protein science. New updates will be given in areas such as protein-protein interactions in drug designs, advances in antibody drug conjugates, bispecific and multispecific antibodies, the expression of difficult proteins, and the purification and characterization of proteins. Don't miss important insights on how to overcome the many hurdles that are associated with the production of proteins.

31 October–4 November 2016 PEGS Europe 2016

EPIC SANA Lisboa Hotel, Lisbon, Portugal

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Over the last three years, participation at PEGS Europe has grown by more than 60%, and this year will be the largest ever. With a more-focused technical program, and double the coverage of the most popular PEGS topics, the 2016 event will feature over 700 attendees, 200 technical presentations, 125 scientific posters, dedicated networking opportunities, exclusive exhibit & poster viewing hours, and interactive roundtable, breakout & panel discussions.

29 September–4 October 2015 7th International Conference on Autoimmunity: Mechanisms and Novel Treatments

Chania, Crete, Greece

At the completion of the meeting the participants should: 1) be able to discuss mechanisms that regulate tolerance and autoimmunity; 2) understand how organ specific and systemic autoimmune diseases arise; 3) understand the rational for the use of biologics (for example anti-TNF, IL-1 inhibitors), drugs (for example cyclosporin, FK506) and gene therapy in the treatment of autoimmune diseases; 4) plan research that will improve the welfare of patients with autoimmune diseases; 5) deliver better care to patients with organ specific and systemic autoimmune diseases.

25–28 April 2015 BIT's Annual International Congress of Antibodies 2015

Nanjing, China

The Annual International Congress of Antibodies (ICA), initiated from 2009, had been successfully organized in Beijing, Hangzhou and Dalian, attracted more than 2,500 participants from 60 countries. ICA series congresses contribute to offering professionals in the field of antibody a multidisciplinary informative cooperative platform, and it have been the most definite and grand Antibody event in Asia. The ICA-2015, with the theme of ”Innovations from Defending Surface to Penetrating the Membrane” will be held on April 25-28, 2015 in Nanjing, China.

3–4 April 2015 8th Annual Proteins & Antibodies Congress 2015

London, UK

Over two days, this meeting will bring together over 400 senior-level decision makers working at the forefront of the proteins and antibodies field in Europe and the US. The conference programme consists of world-class keynote addresses, industry and academic led presentations and panel debates, creating an interactive platform for high-level scientific and business discussion.

18–23 January 2015 Immunology of Fungal Infections: Basic Mechanisms and Translational Implications

Galveston, TX, USA

This conference will bring together the world's leading researchers investigating antifungal immunity, in a setting ideal for promoting cross-disciplinary discussions and collaborations. This will provide a compelling and informative meeting covering the latest advances in the field and the most pressing issues to be tackled.

9–13 November 2014 12th International Congress of Neuroimmunology

Mainz, Germany

There have been exciting developments in the field of Neuroimmunology that affect our understanding of neuroimmune diseases, as well as progress in new immunotherapies and new technology for research. The Organizing Committee, on behalf of the ISNI, has prepared a stimulating program that will inform participants about the latest advances in the field.

3–7 November 2014 PEGS Europe: Protein and Antibody Engineering Summit

Lisbon, Portugal

PEGS Europe is the largest European event covering all aspects of protein and antibody engineering.

23–25 September 2014 5th World Bispecific Antibody Summit

Boston, MA, USA

This year’s 5th World Bispecific Antibody Summit has been designed to empower you, whatever your background, technology or approach, to increase your speed to the clinic. Meet the industry’s finest as we debate the best ways to identify your lead candidate, optimize the drug-like properties and maximize the clinical performance of your bispecific drugs.

10–12 September 2014 Natural Killer Cell Symposium

Hannover, Germany

This international symposium covers all aspects of Natural Killer Cells and is organized annually by the Study Group ‘Biology of Natural Killer Cells’ of the German Society for Immunology.

11–14 August 2014 ImVacS, the Immunotherapies and Vaccine Summit

Boston, MA, USA

This Summit brings together a global audience of vaccine researchers and developers of cancer immunotherapies for five focused meetings that explore the frontiers of immunology as the basis for patient treatment. 250+ researchers from around the world gather to discuss new data, new approaches and novel science from industry, academia, regulatory, and research institutes in a collegial atmosphere that encourages interaction and information sharing.

8–9 May 2014 Antibody-Drug Conjugates

Boston, MA, USA

Antibody-drug conjugates continue to show encouraging therapeutic effects against both solid tumors and hematological malignancies and the number of deals, mergers, partnerships and new companies entering this space has grown as a result. This year’s fourth annual Antibody-Drug Conjugates, as part of the PEGS Summit, will continue to showcase updates from the clinic, and highlight the design of next-generation ADCs.

3–4 April 2014 7th Annual Proteins & Antibodies Congress

London, UK

Our panel of Antibody experts will discuss the latest discovery and development platforms for next generation antibodies. Day Two will feature case studies on the use of engineered antibodies in cancer therapy and the latest insights into targeting difficult receptors and increasing clinical success rate.

The Protein Purification, Expression & Characterisation stream will explore the critical issues in protein crystallisation, assays development, protein production and protein expression.

1–3 April 2014 Protein & Antibody Engineering

Shanghai, China

For program please see:

8–9 April 2013 The 6th Annual Proteins Congress 2013

London, UK

Oxford Global Conferences are proud to present the 6th Annual Proteins Congress 2013, which is to be held on the 8th & 9th April in London, UK. Centered around the key topic areas of Protein Science, Protein Technologies, Expression, Characterisation, Engineering and Production, the event is the single most focused proteins event in Europe. The congress highlights opportunities in the protein and antibody market by focusing on current trends, technologies and business models. The event will also address relevant challenges and bottlenecks, for example, the new Immunogenicity stream offers practical strategies for dealing with one of the industry’s biggest challenges.

12–13 March 2013 The 2nd Monoclonal Antibodies Summit - Advances in Diagnostic & Therapeutic Antibody Development

London, UK

The objective of this conference is to provide communication, education and networking opportunities for scientists engaged in Monoclonal Antibodies whether in academia, biotech or industry.Attendees will hear world-class speakers discussing the challenges and opportunities facing the Monoclonal Antibodies field.

27 January–1 February 2013 Antibodies as Drugs

Vancouver, Canada

Antibodies have come of age as therapeutics since the late-1990s with 26 antibody therapeutics marketed in the USA and ~300 additional antibodies in clinical development. Many of these antibody drugs are targeted to malignant cells and are used for the treatment of a variety of cancers. Participants at this meeting will consider new therapeutic opportunities for antibodies and engineered targeting molecules across a broad range of clinical settings including oncology, autoimmunity and chronic inflammation, infectious diseases and neurology. Progress in molecular engineering to increase their clinical potential will be discussed including antibody-drug conjugates, bispecific and multispecific targeting molecules, effector function enhancement and half-life extension. New frontiers will be explored including engineering antibodies to cross the blood brain barrier and tackling fundamental questions in antibody targeting, mechanisms of action and resistance, and immunogenicity of engineered proteins. This symposium will bring together experts from academia and industry, from molecular engineering to biomedical applications, at the forefront of advancing antibodies as drugs and will be of broad interest to scientists working in this area. Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Cancer Immunology and Immunotherapy, which will share two plenary sessions with this meeting.

2–6 December 2012 IBC's Annual International Conference - Antibody Engineering and Antibody Therapeutics

San Diego, CA, USA

IBC's Antibody Engineering and Antibody Therapeutics conferences are the world's leading forums for the exchange of cutting-edge protein engineering science. Now in its 23rd year, Antibody Engineering has earned its reputation by consistently offering the most current academic research findings and most recent industry updates. Our attendees come back year after year for the information they need to find new approaches to developing novel medicines and vaccines and to improve the safety and efficacy of antibody therapeutics now in development.

Antibody Engineering

  • Antibody Activity and Animal Models
  • Antibody-Targeted CNS Therapy Beyond the Blood Brain Barrier
  • Intellectual Property Issues Impacting Antibody Engineering
  • Deep Sequencing in B Cell Biology and Antibody Libraries
  • New Targets for Antibody-Based Cancer Therapy
  • Systematic Validation of Novel Antibody Targets
  • Systems Medicine in the Future of Immunotherapy

Antibody Therapeutics

  • Antibodies in Clinical Development
  • Clinical Updates of Antibody Drug Conjugates
  • Development Status of Early Stage Therapeutic Antibodies

27–28 November 2012 The 8th annual European Antibody Congress

Geneva, Switzerland

The European Antibody Congress is now 3-congresses in one in 2012, combining the very best of mAb discovery and development with the next generation of Bispecific and Multivalents and Antibody Drug Conjugates.

Showcasing major global trends, recent intra-market clinical progress, best practice and 1-2-1 partnering opportunities, this event delivers unrivalled industry participation across the antibody value chain.

7–9 November 2012 HAH 2012: Human Antibodies & Hybridomas

Orlando, Florida, USA

The HAH 2012 scientific programme will include keynote lectures, contributed papers and poster presentations emphasising all key aspects of human antibody and hybridoma technology, applications and engineering.

10–11 September 2012 Proteins & Biopharma Asia Congress

Singapore City. Singapore

Oxford Global Conferences is proud to present the Proteins & Biopharma Asia Congress 2012, which is to be held on the 10th & 11th September in Singapore. The congress is the single most focused event in Asia Pacific dedicated to key technological and scientific trends in the Asia Biopharmaceutical industry.

The biopharmaceutical market for Asia Pacific revenues is estimated to be around US$ 5.7 billion (2010), with average annual growths rates around 10.3%. This high growth is creating a strong need for production of biopharmaceuticals at higher qualities and volumes as well as developing an effective and efficient bioprocess. The biopharmaceutical industry – antibodies & antibody alternatives, therapeutic Proteins, Antibodies and vaccines – promises success in overcoming these challenges. The Proteins & Biopharma Asia Congress seeks to address the current trends and technologies in advancing upstream and downsteam bioprocesses of proteins, antibodies and vaccines. It will also address the current developments in Protein and Antibody biotherapeutics research, purification & expression systems and recombinant protein therapeutics. Proteins & Biopharma Asia Congress brings together global leaders within biopharmaceutical industry to explore the dynamic strategies, benchmark the latest technologies and offer insights into accelerating growth in the industry.

24–26 July 2012 6th Antibody Engineering & Discovery

Boston, MA, USA

Harnessing the latest advances in strategies and techniques is key to producing better and differentiated antibodies…
Isolating the right lead with the right properties as well as optimising antibody binding, affinity, potency and half life still remain great challenges in antibody development. Competition to create superior drugs is fierce and achieving differentiation has never been so important. Through the development of some of the most successful antibody therapeutics, the world’s largest drug developers have developed a vast range of strategies to overcome universal challenges in preclinical development. These strategies can help you to optimize your antibody discovery and engineering practices and help you realize the potential of improving on existing antibody products already on the market.

20–21 June 2012 BioPharma China Convention 2012-Vaccine & Antibody Focus

Beijing, China

Over the past three years, CDMC Events’ biopharma conference series such as World Clinical Research Organization Summit 2010, Pharma Innovate Asia Taiwan 2010, China Vaccine Focus 2011, World Antibody Focus 2011 etc. have been well received and acclaimed by global participants. In 2012, enlightened by China’s “12th Five Year Plan” on biopharma industry, CDMC Events will present youBioPharma China Convention 2012-Vaccine & Antibody Focuson June 20th-21st in Beijing China with the theme of “Upgrading China’s BioPharma Industry through Innovation and Collaboration”. It is committed to provide a content-rich, critically-focused event with the aim of helping biopharma decision makers and scientists obtain insights into global biopharma trends, China market strategies, partnering & investment opportunities, frontiers in vaccine and antibody R&D, manufacturing & production excellence etc.

3–4 May 2012 13th Annual Antibody Optimization

Boston, MA, USA

The second stage of antibody therapeutic or diagnostic development can sometimes be the most difficult—the optimization.  This conference will present methods researchers can apply to make their antibody the best, most functional and least immunogenic it can be.

3–4 May 2012 2nd Annual Purifying Antibodies

Boston, MA, USA

As demand increases, processes need to escalate in order to produce large numbers of purified antibodies.  Currently, between expression and purification, almost half of the product is lost.  Purification processes need to be improved to enhance recovery, while maintaining antibody quality.

The “Purifying Antibodies” meeting will feature leaders in the field who will share their case studies and experiences both innovating traditional purification techniques and also employing non-traditional approaches that show promising results.  The focus for the differing methods discussed will be “Streamlining Processes” with the aim of providing researchers a greater harvest.

3–4 May 2012 2nd Annual Antibody-Drug Conjugates

Boston, MA, USA

Antibody-drug conjugates (ADCs) in late-stage clinical development have shown encouraging therapeutic effects against both solid tumors and hematological malignancies. Significant progress has been made through optimization of parameters including specificity, potency, linker technology, conjugate site design, and the stoichiometry and placement of drugs.

These sessions will showcase the design and discovery of next generation ADC’s, leveraging current knowledge from successful clinical candidates.

2–3 May 2012 13th Annual Engineering Antibodies

Boston, MA, USA

Therapeutic and diagnostic antibodies continue to make inroads in biomedicine, but the successful application of these products requires smart discovery and development.  This conference will explore the latest methods to overcome challenges and open new opportunities for making these valuable proteins viable.

2–3 May 2012 3rd Annual Bispecific Antibodies

Boston, MA, USA

Bispecific and multiclonal antibodies are one of the most promising and exciting areas of protein engineering. Since 2009, there have been deals made in excess of $6.5 billion on bispecifics, and the range of therapeutic uses for bispecific antibodies are being expanding beyond oncology to diseases of the immune system, heart and CNS.

This meeting will explore the remaining challenges and profile creative problem solving that has been used to make successful bispecific formats.  The latest approaches for dual-targeting as well as targeting two different epitopes of the same receptor will be explored for improving efficacy.

30 April–1 May 2012 2nd Annual Antibodies for Cancer Therapy

Boston, MA, USA

The field of antibodies directed against cancer is burgeoning and this is a huge growth area due to the success of drugs already on the market.  There still remain a number of challenges that include reducing immunogenicity, improving the targeting in solid tumors, and increasing the ability to kill cancer cells.

The pre-clinical and clinical results of recent new constructs will be shared, and the changes in regulation of antibodies will be reviewed.  The latest new approaches will be compared to more established techniques for filling the pipeline with future best-in-class drugs.

28–29 April 2012 Emerging Antibody and Protein Engineering Partnering Forum

Boston, MA, USA

This focused partnering event provides greater depth of company coverage across a more narrow range of topics compared to typical partnering events. Presenting companies will be selected on the basis of competitive review of submitted proposals, as judged by the organizer and members of the Program Advisory Board, many of whom will also be participating in Panel Discussions at the beginning of each session of the program. Time is also provided for scheduling of one-on-one discussions, as well as networking time for unscheduled exploration of potential partnerships.

26–28 March 2012 BIT's 4th International Conference of Antibodies-2012

Beijing, China

More than 300 presentations covering science, technology, business, economics and policy in the field of antibodies by distinguished scientists and businessmen. Presentation of 200 posters and 100 exhibitions of new products and technologies to an audience of over 800 people. Round table discussions to create network and marketing opportunities for your business. Career fairs, poster sessions, expositions for both academia and industries. Tour to famous regions of China including Beijing and Xi'an

26–28 March 2012 International Congress of Antibodies

Beijing, Shanghai

International Congress of Antibodies is a premier conference, which aims to provide a forum for presentation of new research results and demonstration of new systems and techniques in the broad field of information technology and management. Information Technology supports varied organizations for the decision making. In the recent years antibody engineering and technology has came out as one of the mainstream biomedical areas; it plays a vital role in pharmaceutical and medical industries. International Congress of Antibodies will provide round table discussions to create network and marketing opportunities for expanding business. Young Scientist Forum will be also provided for the youngsters and new comers in the industry of science.

25–30 March 2012 Antibody Biology & Engineering

Galveston, TX, USA

This second Antibody Biology & Engineering GRC will provide this opportunity in a collegial and highly interactive environment that typifies the Gordon Research Conferences. Leading experts and thought leaders both from academia and industry will share their most recent findings on topics of broad interest to the attendees. Investigators and trainees at all levels will have many opportunities for presenting of their new, exciting results in poster sessions and selected oral presentations, with ample time for discussion, networking and brainstorming.

18–22 March 2012 Mutations, Malignancy and Memory - Antibodies and Immunity

Boston, Massachusetts

Mutations in the human genome are regarded as potentially disastrous events that lead to carcinogenesis. From the vantage point of B cell immunology, however, programmed DNA alterations at the antibody gene loci are essential for efficient antibody responses. A plethora of recent findings are beginning to illuminate open questions about the precise molecular mechanisms of these diversification processes, their regulation, and how errors in these pathways lead to cancer. Furthermore, the very same class of mutator enzymes plays an underappreciated role in non-lymphoid cancers, in antiviral responses and in epigenetic reprogramming. Antibody diversification not only shapes the repertoires of the immunological memory, but also those of auto-antibodies. The Keystone Symposia meeting on Mutations, Malignancy and Memory – Antibodies and Immunity will provide both a platform to integrate these more or less isolated fields and an opportunity to identify interfaces that could be relevant for therapeutic approaches in malignancies and autoimmune diseases.

13 March–14 February 2012 Monoclonal Antibodies Conference: Exploring Innovation in Therapeutic Antibody Development and Production

London, UK

The objective of this conference is to provide communication, education and networking opportunities for scientists engaged in Monoclonal Antibodies whether in academia, biotech or industry.Attendees will hear world-class speakers discussing the challenges and opportunities facing the Monoclonal Antibodies field.

20–23 February 2012 Antibodies Asia 2012

Shanghai, China

Antibody-based therapeutics currently enjoys exceptional success in the global biologic drug market. Achieving a total sale of nearly US$35 billion and holding six spots out of the top 20 best-selling pharmaceutical products in 2008, monoclonal antibodies (mAb) sales are predicted to grow exponentially to reach US$50 billion in 2013.

Rising research interest is further compelled by the large market potential that these substances may offer. Its ability to treat a wide range of complex diseases relating to oncology, inflammation and autoimmune diseases make the development of novel, proprietary antibodies top on every biopharmaceutical companies’ list. In addition, biosimilar antibodies on its own also represent a huge, multibillion-dollar opportunity for generic manufactures in the United States, Europe and Asia.

With the latest hype in biosimilar antibodies and promising success in developing bi-specific antibodies using new platform, the advancement in the field of therapeutic antibodies unravel more commercial opportunities and renewed optimism for the industry, making it an even more lucrative and dynamic market for investors.

Join us at IBC’s 4 th Annual Antibody Asia conference to learn about the latest antibody research and development, industry trends and updates and ways to expedite your antibody pipeline into revenue-generating biologics. Held from 20 th to 22 nd February in Shanghai, we promise to put together the most beneficial and multi-faceted agenda, delivered by internationally renowned speakers, specially catered to match your interest.

17–19 January 2012 5th Annual Recombinant Antibodies Conference

London, UK

Louise Holliday will be speaking at Visiongain’s 5th Annual Recombinant Antibodies conference.  The conference will allow delegates to:

  • Network with key decision makers at leading companies
  • Improve the potency of IgG molecules for ADCC, ADCP and CDC applications
  • Enhance immune effector functions through targeted Fc region engineering
  • Increase in vivo circulation time with conjugated immunoglobulins
  • Extend pharmacokinetic half-life and exposure
  • Better utilise, deploy and evaluate in silico tools during early-phase research
  • Optimise antigen-binding domains
  • Engineer decreased immunogenicity, cross-reactivity and in vivo toxicity
  • Assess new technologies for selecting antibody attributes
  • Maximise site-specific drug loading for bispecific antibodies
  • Obtain new data on inflammatory disease, and solid and liquid cancer targets
  • Block activation of angiogenic signalling pathways and disrupt the tumour microenvironment

11–12 January 2012 Antibodies for the 21st Century

San Diego, CA, USA

Innovating antibody therapeutics requires novel discovery platforms, computational insights, and engineering enhanced properties, such as binding specificity, PK and half-life.  This meeting focuses on the strategies and technologies used in the highly complex efforts to manipulate antibodies for creating next-generation therapeutics. Join with key leaders from around the world in a relaxed, congenial atmosphere to discuss the latest advances in the development of therapeutic antibodies.

4–8 December 2011 22nd Annual Antibody Engineering and Antibody Therapeutics

Hilton San Diego Bayfront Hotel, San Diego, CA, USA

Call for Papers Categories

Antibody Engineering

  • Antibodies as Probes of Structure
  • Antibodies as Signaling Modifiers: Where Did We Go Right? And, Can We Learn from Success?
  • Antibodies in a Complex Environment
  • Computational Success and Failure in Antibody Binding Site Prediction
  • Model-Guided Generation of Binding Sites
  • Novel Selection Strategies
  • Rational Vaccine Design
  • Structure and Dynamics of Antibodies and Membrane Receptor Targets
  • The Biology Behind Potential Blockbuster Antibodies

Antibody Therapeutics

  • 25 years of Therapeutic Antibodies: Lessons Learned and Future Challenges
  • Clinical Updates of Therapeutic Antibodies
  • Drug Conjugates and Bispecifics
  • Next Generation Anti-Angiogenic Therapeutic Antibodies
  • Preclinical and Early Stage Development of Therapeutic Antibodies

Submission Deadline: Friday, April 22, 2011

29 November–1 December 2011 7th annual European Antibody Congress 2011

Crowne Plaza, Geneva, Switzerland

The European Antibody Congress is the world’s leading conference addressing critical scientific issues and strategic industry challenges associated with therapeutic mAb development. Showcasing major antibody structural improvements, global trends, recent intra-market authorisation and clinical progress, this event sees unrivalled industry participation. Hear, learn, debate and act on the most critical scientific and business opportunities in the antibody sector.

The 250+ audience is primarily made up of Pharmaceutical companies and Biotechs. Supporting their projects, Technology Providers, CROs, CMOs and Researchers also attend. Over 50 leading scientists from Big Pharma and specialised biotech companies will share their expertise and groundbreaking conclusions throughout three jampacked days.

Speakers include: Merrimack Pharmaceuticals Inc, Schering Pharma AG, Lonza Custom Manufacturing, Wilex AG, Eli Lilly and Company, GenMab, Morphotek Inc, University of Zurich, Tufts Centre for the Study of Drug Development and mAbs journal, Ablynx,  Kenta Biotech AG, Pfizer  Global Biologics, CBER/FDA, Protagen AG, MedImmune, Roche Glycart AG, Icosagen Cell Factory OU, Johnson & Johnson, Fresenius Kabi, Bayer, Genentech, Inc, Centre d'Immunology and Vaccinex.

24–26 May 2011 World Antibody Manufacturing & Development Summit

Boston, MA, USA

With many blockbusting antibody therapeutics hitting the market, and even more to follow over the next few years, it is crucial that supply keeps up with demand.

Several productivity bottlenecks need to be overcome in order to optimize the efficiency of antibody processing.

Following 2010’s successful meeting, Hanson Wade is again hosting the World Antibody Manufacturing & Development Summit to bring together thought leaders to drive antibody development forward.

  • Get the latest market intelligence on the biosimilar landscape. Hear what next generation technologies can keep you ahead of the game
  • Discover how to manage the lifecycle of a QbD product
  • Be updated on the post-approval lifecycle management (PALM) plan that is being developed for antibody products undergoing licensing with QbD
  • Refine your strategy for rapid transfer of protein therapeutics into existing manufacturing facilities
  • See case studies of creative solutions to downstream capacity to maximise high cell culture productivity
  • Learn about the best ways to approach the regulators and how QbD approaches can be included in regulatory submissions
  • Acquire the key design tips for enhancing CMC probability of success
  • Get advice on how to implement single-use processing across all unit operations
  • Hear the latest case studies on antibody formulations, including stability comparability approaches, changing drug substance container, and the implications of moving to higher titers
  • Get an insight into the latest techniques for high-throughput screening of chromatography resins

30 November–2 December 2009 European Antibody Congress 2009

Geneva, Switzerland

The 5th annual European Antibody Congress is the Antibody industry\'s number one congress for addressing the R&D, commercial application and manufacture of antibodies across the whole therapeutic landscape.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top